Phase I of BKM120/Olaparib for Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2014 by Dana-Farber Cancer Institute
Sponsor:
Collaborators:
Novartis
AstraZeneca
Information provided by (Responsible Party):
Ursula A. Matulonis, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01623349
First received: June 7, 2012
Last updated: February 6, 2014
Last verified: February 2014
  Purpose

This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational combination of drugs. Phase I studies also try to define the appropriate dose of the investigational combination to use for further studies. "Investigational" means that the combination of these drugs is still being studied and that research doctors are trying to find out more about it. It also means that the FDA has not approved either of these drugs nor the combination of being tested for use in patients, including people with your type of cancer.

BKM120 and olaparib are drugs that may stop cancer cells from growing abnormally. These drugs when combined in laboratory experiments with animals, have demonstrated anti-cancer activity. Information from these other research studies suggests that both of these agents BKM120 and olaparib, may help to shrink tumor cells in the types of cancers being studied in this research study.

In this research study, the investigators are looking for the highest dose that can be given safely and also to see if the combination of BKM120 and olaparib is effective in treating your type of cancer.


Condition Intervention Phase
Ovarian Cancer
Breast Cancer
Drug: BKM120 and Olaparib
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer

Resource links provided by NLM:


Further study details as provided by Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • Determine MTD for the Combination of BKM120 and Olaparib [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    To determine the maximally tolerated dose (MTD) and recommended phase 2 dose (RP2D) of the combination of BKM120 and olaparib in patients with recurrent TNBC and HGSC.


Secondary Outcome Measures:
  • Determine the overall Safety and Observed Toxicities of combining BKM120 and Olaparib [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    To determine the safety and observed toxicities of the combination of BKM120 and olaparib in this population

  • Determine Pharmacokinetics of BKM120 and Olaparib [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

    To measure the drug levels of both BKM120 and olaparib at different time points after they are started to see if either drug affects the metabolism and levels of the other. PK's samples will be drawn in duplicate (one set to be sent to Astrazeneca and the second set to Novartis). BKM120 and olaparib levels will be performed at the following timepoints:

    1. prior to taking both BKM120 and olaparib cycle 1, day 1.
    2. Cycle 1, day 8: prior to dosing, 1, 2, 4, and 8 hours post am dosing.
    3. Cycle 1, day 15: prior to dosing, 1, 2, 4, and 8 hours post am dosing.

  • Determine preliminary activity of this combination at the MTD and RP2 dose [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To determine a preliminary anti-cancer activity of this combination at the MTD and RP2D dose. Anti-cancer activity of this combination will be measured by response rate by RECIST 1.1 in patients who have measurable cancer

  • Exploratory Translational Endpoints [ Time Frame: 2 years ] [ Designated as safety issue: No ]

    (A) To determine the downstream signaling effects of the PI3-kinase pathway whenboth PI3-kinase and PARP are inhibited.

    (B) To determine BRCA1 immnostaining, BRCA1 promoter hypermethylation and somatic mutations in BRCA1 and BRCA2 in archived formalin fixed paraffin embedded (FFPE) tissue and any new available tissues (pre- or post-treatment biopsies and biopsies or other tumor colelction for clinical care at the time of or following tumor progression)



Estimated Enrollment: 56
Study Start Date: September 2012
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment Arm
BKM120 and Olaparib
Drug: BKM120 and Olaparib
Olaparib twice daily (starting dose 50 mg) and BKM120 once daily (starting dose 40 mg). Both drugs are given orally.
Other Names:
  • Olaparib (NSC 747856)
  • BKM120 (IND 102823)

  Hide Detailed Description

Detailed Description:

During this study, additional tests will be performed on a sample of your original tumor that has been stored in your institution's tissue banks. These tests will be performed on tumor tissue samples from previous biopsies or surgeries for your cancer. The research done on these samples will involve looking at DNA and proteins in your cancer to see if researchers can learn more about your type of cancer and understand how this combination of drugs might work on your tumor. Testing of this sample will not require you to undergo any additional research procedures.

Approximately 2 tablespoons of blood will be collected for research testing. This testing will involve looking at DNA and proteins in your blood to compare them with those seen in your cancer. This will be drawn before you begin taking the study drug.

Participants in the dose expansion portion of the study may be asked to have a tumor biopsy done. The dose expansion phase occurs after the appropriate dose for the combination of BKM120 and Olaparib has been determined. Your doctor will tell you if you are in this portion of the trial. Before and after you begin taking BKM120 and olaparib, your doctor may also ask you to participate in an optional study where you would have tumor biopsies done.

You may also participate in an optional blood test for the BRCA gene. Approximately 2 teaspoons of blood will be taken for this test. The BRCA gene test is a blood test that uses DNA analysis to see changes in either one of two breast cancer genes, known as BRCA1 or BRCA2. After having a BRCA gene test performed, you learn whether you carry an inherited BRCA gene mutation. If your blood is tested for the BRCA gene, the results will be reported to your study doctor who will share the results with you and provide information related to your personal risk of breast cancer. Having a BRCA gene mutation is rare, occurring in only about 1 in 1000 people. Inherited BRCA gene mutations are responsible for less than 5 to 10 percent of breast cancers and about 10 to 15 percent of ovarian cancers.

Participation in the tumor biopsy and blood test for the BRCA gene are optional, and whether you consent or refuse to undergo these additional tests will not affect your participation in the main research study.

Since the investigators are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have high grade serious ovarian cancer or triple negative breast cancer, not everyone who participates in this research study will receive the same dose of the study drug. The dose you get will depend on the number of participants who have been enrolled in the study before you and how well they have tolerated their doses.

Both drugs are in oral form. If you take part in this research study, you will be given a study dosing calendar for each drug for each treatment cycle. Each treatment cycle lasts 4 weeks. BKM120 should be taken once daily in the morning, one hour after a light meal. Olaparib should be taken twice a day continuously, about twelve hours apart. The olaparib morning dose should be taken at the same time as BKM120 one hour after a light meal. The evening dose can also be taken one hour after a light meal or on an empty stomach either 1 hour before or 2 hours after meals. If you vomit either or both medications, record this on your diary and do not take another dose that day.

The investigators will assess your tumor by CT or MRI scan every 8 weeks. During Cycle 1, you will come into the clinic every week, and during cycle 2, you will come into clinic every 2 weeks. For all cycles thereafter, you will come in once every 4 weeks.

During study visits you will undergo some or all of the following: evaluation of performance status, recording of any healthy problems, physical exam including vital signs, list of medications taken since last visit, questionnaire to evaluate anxiety and depression, routine blood tests, research blood tests, Electrocardiogram and optional biopsy.

You will remain in this research study as long as you are benefitting from study treatment. If you are removed from the research study for any reason you may be followed for up to one year.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed recurrent high grade serous ovarian cancer or triple negative breast cancer
  • Subjects with recurrent, metastatic triple negative breast cancer must have had at least 1 chemotherapy regimen for metastatic breast cancer or have developed metastatic breast cancer within 1 year of completion of adjuvant chemotherapy
  • Prior therapy for high grade serous ovarian cancer subjects must have included a first-line platinum-based regimen
  • At least 4 weeks since prior radiation therapy, 3 weeks since prior chemotherapy and 6 weeks if the last regimen included BCNU or mitomycin C
  • At least 4 weeks since any small-molecular kinase inhibitors or any other type of investigational agent
  • Life expectancy of at least 4 months
  • Able to swallow and tolerate oral medications

Exclusion Criteria:

  • Evidence of bowel obstruction, abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of study entry
  • Current dependency on IV hydration or total parental nutrition
  • Diabetes mellitus unless well controlled
  • Pregnant or breast feeding
  • History of grade 3 or 4 toxicities with previous PI3kinase inhibitor or PARP inhibitor
  • Current or active dermatologic diagnoses that would preclude interpretation of skin toxicities of BKM120
  • Receiving any medications or substances that are strong inhibitors or inducers of CYP3A4
  • History of cardiac dysfunction or disease
  • Persistent toxicities (greater than or equal to CTCAE grade 2) caused by previous cancer therapy
  • Major surgery within 14 days of starting study treatment
  • Evidence of coagulopathy or bleeding diathesis
  • History of major depressive episode, bipolar disorder, obsessive/compulsive disorder, schizophrenia, history of suicide attempt or ideation or homicide/homicidal ideation
  • CTCAE grade 3 or greater anxiety
  • Uncontrolled, intercurrent illness
  • Known HIV positive and on combination antiretroviral therapy
  • Receiving chronic treatment with steroids or another immunosuppressive agent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01623349

Contacts
Contact: Christin Whalen, RN 617-632-7738 cwhalen@partners.org
Contact: Philippa Quy 617-632-6944 pquy@partners.org

Locations
United States, Massachusetts
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Christin Whalen, RN    617-582-7738    cwhalen@partners.org   
Contact: Kristin Meegan    617-632-6617    kmeegan@partners.org   
Principal Investigator: Ursula Matulonis, MD         
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Michelle Wright    617-726-2969    mwright10@partners.org   
Principal Investigator: Michael Birrer, MD, PhD         
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: Susan McIntyre    617-667-1940    smcintyr@bidmc.harvard.edu   
Contact: Robert Shaw    617-667-5987    rdshaw@bidmc.harvard.edu   
Principal Investigator: Gerburg Wulf, MD         
United States, New York
Memorial Sloan-Kettering Cancer Center Recruiting
New York City, New York, United States, 10065
Contact: Katherine Bell-McGuinn, MD    646-888-4221    bell-mck@mskcc.org   
Principal Investigator: Katherine Bell-McGuinn, MD         
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77230
Contact: Shannon Westin, RN    713-794-4314      
Principal Investigator: Shannon Westin, MD         
Sponsors and Collaborators
Dana-Farber Cancer Institute
Novartis
AstraZeneca
Investigators
Principal Investigator: Ursula A. Matulonis, M.D. Dana-Farber Cancer Institute
  More Information

No publications provided

Responsible Party: Ursula A. Matulonis, MD, Principal Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT01623349     History of Changes
Other Study ID Numbers: 12-159
Study First Received: June 7, 2012
Last Updated: February 6, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Dana-Farber Cancer Institute:
Recurrent
High Grade
Serous
Triple Negative

Additional relevant MeSH terms:
Breast Neoplasms
Ovarian Neoplasms
Triple Negative Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Endocrine Gland Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders

ClinicalTrials.gov processed this record on August 28, 2014